Mosaic ImmunoEngineering Inc. (CPMV) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Huntington Beach, CA, アメリカ. 現CEOは Steven W. King.
CPMV を有する IPO日 2013-01-02, 2 名の正社員, に上場 Other OTC, 時価総額 $5.03M.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
